Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 358

1.

Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.

Wong PC, White A, Luettgen J.

Hosp Pract (1995). 2013 Feb;41(1):19-25. doi: 10.3810/hp.2013.02.1009.

PMID:
23466964
2.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
3.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
4.

Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

Cuker A, Siegal DM, Crowther MA, Garcia DA.

J Am Coll Cardiol. 2014 Sep 16;64(11):1128-39. doi: 10.1016/j.jacc.2014.05.065. Review.

5.

[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].

Dumont B, Faille D, Ajzenberg N.

Med Sci (Paris). 2011 May;27(5):493-500. doi: 10.1051/medsci/2011275014. Epub 2011 May 25. Review. French.

6.

Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication.

Sadeghi N, Kahn D, Jeske W, Hoppensteadt D, Fareed J.

Clin Appl Thromb Hemost. 2013 Nov-Dec;19(6):589-99. doi: 10.1177/1076029613479819. Epub 2013 Mar 4.

PMID:
23463187
7.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

8.

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

Wong PC, Crain EJ, Watson CA, Xin B.

J Thromb Haemost. 2009 Aug;7(8):1313-20. doi: 10.1111/j.1538-7836.2009.03503.x. Epub 2009 Jun 3.

9.

[New anticoagulants: dabigatran, rivaroxaban and apixaban].

Vargas Ruiz AG, Ramírez López AN, Medina Viramontes ME.

Gac Med Mex. 2012 May-Jun;148(3):257-64. Review. Spanish.

10.
11.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

12.

Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.

Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R.

Thromb Haemost. 2014 May 5;111(5):989-95. doi: 10.1160/TH13-07-0607. Epub 2013 Dec 19.

PMID:
24352511
13.

Newer clinically available antithrombotics and their antidotes.

Lévy S.

J Interv Card Electrophysiol. 2014 Sep;40(3):269-75. doi: 10.1007/s10840-014-9910-2. Epub 2014 Jun 18. Review.

PMID:
24934756
14.
15.

Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.

Hosokawa K, Ohnishi T, Sameshima H, Miura N, Koide T, Maruyama I, Tanaka KA.

PLoS One. 2014 Jan 31;9(1):e86491. doi: 10.1371/journal.pone.0086491. eCollection 2014.

16.

Laboratory monitoring of the non-vitamin K oral anticoagulants.

Blann AD, Lip GY.

J Am Coll Cardiol. 2014 Sep 16;64(11):1140-2. doi: 10.1016/j.jacc.2014.07.010. No abstract available.

17.

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.

Ufer M.

Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. Review.

PMID:
20135071
18.

Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.

Peacock WF.

Hosp Pract (1995). 2014 Oct;42(4):75-82. doi: 10.3810/hp.2014.10.1144.

PMID:
25502131
19.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
20.

Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.

Morales-Vidal S, Schneck MJ, Flaster M, Biller J.

Expert Rev Neurother. 2012 Feb;12(2):179-89; quiz 190. doi: 10.1586/ern.11.185. Review.

PMID:
22288673

Supplemental Content

Support Center